Nemolizumab Approved for Adults with Prurigo Nodularis
XTalks
AUGUST 14, 2024
The US Food and Drug Administration (FDA) has approved Galderma’s monoclonal antibody Nemluvio (nemolizumab) for the treatment of adult patients with the chronic skin condition prurigo nodularis. Monoclonal antibody therapy has been found to have fewer side effects when compared to immunosuppressant drugs.
Let's personalize your content